Clinical Trials Logo

Clinical Trial Summary

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02112526
Study type Interventional
Source Acerta Pharma BV
Contact
Status Active, not recruiting
Phase Phase 1
Start date August 7, 2014
Completion date April 1, 2026